Company intelligence / Profile preview

PINS Medical

Beijing, Beijing, Chinapinsmedical.com ↗

Ownership: Private
Employees: ~250
Development stage: Commercial

Overview

PINS Medical has developed and commercialized a range of neuromodulation devices for the treatment of neurological disorders. Their products are used clinically for conditions such as Parkinson's disease, epilepsy, chronic pain syndromes, and urinary incontinence. The company collaborates with leading academic institutions like Tsinghua University to advance research and clinical applications.

Therapeutic areas: NephrologyNeurology
Modalities: Device (specifically neuromodulation devices including deep brain stimulation, vagus nerve stimulation, spinal cord stimulation, sacral neuromodulation)
Industry: Implantable Medical Devices

Partnerships

Science Magazine (“Science-PINS Prize of Neuromodulation” partnership)Tsinghua University (“National Engineering Laboratory for Neuromodulation” collaboration)

Beyond the preview

Go deeper on PINS Medical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PINS Medical.

Explore the full profile